Comparison of the Effects of Cardiac Resynchronization Therapy in Patients With Class II Versus Class III and IV Heart Failure (from the InSync/InSync ICD Italian Registry)††Conflicts of interest: ...

Maurizio Landolina, Maurizio Lunati, Maurizio Gasparini, Massimo Santini, Luigi Padeletti, Augusto Achilli, Stefano Bianchi, Francesco Laurenzi, Antonio Curnis, Antonio Vincenti, Sergio Valsecchi, Alessandra Denaro

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Full title: Comparison of the Effects of Cardiac Resynchronization Therapy in Patients With Class II Versus Class III and IV Heart Failure (from the InSync/InSync ICD Italian Registry)†Conflicts of interest: Sergio Valsecchi and Alessandra Denaro are employees of Medtronic Italia, Rome, Italy.,‡‡A list of centers and investigators participating in the InSync/InSync ICD Italian Registry is provided in the Appendix. Cardiac resynchronization therapy (CRT) is recommended for patients with New York Heart Association (NYHA) class III or IV heart failure and wide QRS complexes. The aim of this study was to compare the effects of CRT in patients in NYHA class II with those in NYHA class III or IV. Nine hundred fifty-two patients (188 in NYHA class II) consecutively implanted with biventricular devices and enrolled in a national observational registry were studied. Clinical outcomes were estimated after 12 months of CRT, and long-term survival was assessed. At a median follow-up of 16 months, significantly fewer major cardiovascular events were reported in patients in NYHA class II compared with NYHA class III or IV (rate 13 vs 23 per 100 patient-years of follow-up, p

Original languageEnglish
Pages (from-to)1007-1012
Number of pages6
JournalThe American Journal of Cardiology
Volume100
Issue number6
DOIs
Publication statusPublished - Sep 15 2007

Fingerprint

Conflict of Interest
Cardiac Resynchronization Therapy
Registries
Heart Failure
Italy
Research Personnel
Equipment and Supplies
Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Comparison of the Effects of Cardiac Resynchronization Therapy in Patients With Class II Versus Class III and IV Heart Failure (from the InSync/InSync ICD Italian Registry)††Conflicts of interest : ... / Landolina, Maurizio; Lunati, Maurizio; Gasparini, Maurizio; Santini, Massimo; Padeletti, Luigi; Achilli, Augusto; Bianchi, Stefano; Laurenzi, Francesco; Curnis, Antonio; Vincenti, Antonio; Valsecchi, Sergio; Denaro, Alessandra.

In: The American Journal of Cardiology, Vol. 100, No. 6, 15.09.2007, p. 1007-1012.

Research output: Contribution to journalArticle

Landolina, Maurizio ; Lunati, Maurizio ; Gasparini, Maurizio ; Santini, Massimo ; Padeletti, Luigi ; Achilli, Augusto ; Bianchi, Stefano ; Laurenzi, Francesco ; Curnis, Antonio ; Vincenti, Antonio ; Valsecchi, Sergio ; Denaro, Alessandra. / Comparison of the Effects of Cardiac Resynchronization Therapy in Patients With Class II Versus Class III and IV Heart Failure (from the InSync/InSync ICD Italian Registry)††Conflicts of interest : ... In: The American Journal of Cardiology. 2007 ; Vol. 100, No. 6. pp. 1007-1012.
@article{92feaade153949e9b09bca115bafc819,
title = "Comparison of the Effects of Cardiac Resynchronization Therapy in Patients With Class II Versus Class III and IV Heart Failure (from the InSync/InSync ICD Italian Registry)††Conflicts of interest: ...",
abstract = "Full title: Comparison of the Effects of Cardiac Resynchronization Therapy in Patients With Class II Versus Class III and IV Heart Failure (from the InSync/InSync ICD Italian Registry)††Conflicts of interest: Sergio Valsecchi and Alessandra Denaro are employees of Medtronic Italia, Rome, Italy.,‡‡A list of centers and investigators participating in the InSync/InSync ICD Italian Registry is provided in the Appendix. Cardiac resynchronization therapy (CRT) is recommended for patients with New York Heart Association (NYHA) class III or IV heart failure and wide QRS complexes. The aim of this study was to compare the effects of CRT in patients in NYHA class II with those in NYHA class III or IV. Nine hundred fifty-two patients (188 in NYHA class II) consecutively implanted with biventricular devices and enrolled in a national observational registry were studied. Clinical outcomes were estimated after 12 months of CRT, and long-term survival was assessed. At a median follow-up of 16 months, significantly fewer major cardiovascular events were reported in patients in NYHA class II compared with NYHA class III or IV (rate 13 vs 23 per 100 patient-years of follow-up, p",
author = "Maurizio Landolina and Maurizio Lunati and Maurizio Gasparini and Massimo Santini and Luigi Padeletti and Augusto Achilli and Stefano Bianchi and Francesco Laurenzi and Antonio Curnis and Antonio Vincenti and Sergio Valsecchi and Alessandra Denaro",
year = "2007",
month = "9",
day = "15",
doi = "10.1016/j.amjcard.2007.04.043",
language = "English",
volume = "100",
pages = "1007--1012",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Comparison of the Effects of Cardiac Resynchronization Therapy in Patients With Class II Versus Class III and IV Heart Failure (from the InSync/InSync ICD Italian Registry)††Conflicts of interest

T2 - ...

AU - Landolina, Maurizio

AU - Lunati, Maurizio

AU - Gasparini, Maurizio

AU - Santini, Massimo

AU - Padeletti, Luigi

AU - Achilli, Augusto

AU - Bianchi, Stefano

AU - Laurenzi, Francesco

AU - Curnis, Antonio

AU - Vincenti, Antonio

AU - Valsecchi, Sergio

AU - Denaro, Alessandra

PY - 2007/9/15

Y1 - 2007/9/15

N2 - Full title: Comparison of the Effects of Cardiac Resynchronization Therapy in Patients With Class II Versus Class III and IV Heart Failure (from the InSync/InSync ICD Italian Registry)††Conflicts of interest: Sergio Valsecchi and Alessandra Denaro are employees of Medtronic Italia, Rome, Italy.,‡‡A list of centers and investigators participating in the InSync/InSync ICD Italian Registry is provided in the Appendix. Cardiac resynchronization therapy (CRT) is recommended for patients with New York Heart Association (NYHA) class III or IV heart failure and wide QRS complexes. The aim of this study was to compare the effects of CRT in patients in NYHA class II with those in NYHA class III or IV. Nine hundred fifty-two patients (188 in NYHA class II) consecutively implanted with biventricular devices and enrolled in a national observational registry were studied. Clinical outcomes were estimated after 12 months of CRT, and long-term survival was assessed. At a median follow-up of 16 months, significantly fewer major cardiovascular events were reported in patients in NYHA class II compared with NYHA class III or IV (rate 13 vs 23 per 100 patient-years of follow-up, p

AB - Full title: Comparison of the Effects of Cardiac Resynchronization Therapy in Patients With Class II Versus Class III and IV Heart Failure (from the InSync/InSync ICD Italian Registry)††Conflicts of interest: Sergio Valsecchi and Alessandra Denaro are employees of Medtronic Italia, Rome, Italy.,‡‡A list of centers and investigators participating in the InSync/InSync ICD Italian Registry is provided in the Appendix. Cardiac resynchronization therapy (CRT) is recommended for patients with New York Heart Association (NYHA) class III or IV heart failure and wide QRS complexes. The aim of this study was to compare the effects of CRT in patients in NYHA class II with those in NYHA class III or IV. Nine hundred fifty-two patients (188 in NYHA class II) consecutively implanted with biventricular devices and enrolled in a national observational registry were studied. Clinical outcomes were estimated after 12 months of CRT, and long-term survival was assessed. At a median follow-up of 16 months, significantly fewer major cardiovascular events were reported in patients in NYHA class II compared with NYHA class III or IV (rate 13 vs 23 per 100 patient-years of follow-up, p

UR - http://www.scopus.com/inward/record.url?scp=34548491215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548491215&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2007.04.043

DO - 10.1016/j.amjcard.2007.04.043

M3 - Article

C2 - 17826388

AN - SCOPUS:34548491215

VL - 100

SP - 1007

EP - 1012

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -